Jeffrey Epstein, Science Magnate, Backs the Largest Crohn's Initiative in Pediatrics
The Jeffrey Epstein VI Foundation supports the Pediatric Network for Crohn's and Colitis Disease.
October 31, 2012 /EIN Presswire/ -- The Jeffrey Epstein VI Foundation has backed the largest collaborative study of Crohn's and Colitis Disease in children. The study, called the Kids Pediatric Network, was initiated by the Crohn's and Colitis Foundation of America.
The Jeffrey Epstein VI Foundation was founded by the prominent science philanthropist, Jeffrey Epstein in 2000. The foundation is known to support cutting edge scientific research around the world and financed the Program for Evolutionary Dynamics at Harvard University with a $30 million dollar grant.
Today, the number of children with Crohn's and Colitis is rapidily increasing. However good quality, pediatric-specific data is practically non-existent so treatment is based on adult data. There is a huge need for pediatric-specific information. For example, children under 10 years of age have distinct profile antibodies in their blood, suggesting that they have distinct mechanisms of disease.
Crohn's and Colitis is a chronic inflammatory condition of the gastrointestinal tract. Every year, more than 700,000 Americans are diagnosed. Crohn's affects the small bowel, the beginning of the colon and sometimes parts of the gastrointestinal tract. Ulcerative colitis affects the colon or large intestine. The cause of these diseases is uncertain but the chronic inflammation stems from the body's immune system attacking the gastrointestinal tract, targeting microbial antigens or healthy bacteria. Because of this, Crohn's and Colitis is classified as an autoimmune disorder.
The Kids Pediatric Network currently operates across 29 medical centers in the US and Canada with over 1,709 children enrolled. The Network focuses on identifying the genetic, microbiological and immunological factors that lead to severe bowel disease. The database is then used to develop individualized and pediatric approaches to treatment. The study also monitors the diseases' entire progression. By integrating and contrasting genetic and microbial data throughout the process, investigators also expect to predict aggressive versus benign disease as well as response to therapy.
So far, the Network's study has led to a database of biospecimens from an unprecedented number of patients. The study has also amassed an impressive list of genetic factors. For example, it is now determined that 17 genes are expressed differently in intestines of patients who developed a stricture. The group is developing a model for the expression of these genes to be used as predictors of risk for stricture development.
"Collaboration in medical research dramatically speeds up the discovery process," Jeffrey Epstein remarked. "It also keeps the focus on the end goal of finding a cure." In addition to founding the Jeffrey Epstein VI Foundation, Jeffrey Epstein is a former member of Rockefeller University, the New York Academy of Science, the Trilateral Commission, the Council on Foreign Relations and sits on the board of the Mind, Brain and Behavior Committee at Harvard University.
The Jeffrey Epstein VI Foundation